Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. The company is headquartered in Waltham, Massachusetts and currently employs 1,778 full-time employees. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
How did RGEN's recent EPS compare to expectations?
The most recent EPS for Repligen Corp is $0.48, beating expectations of $0.39.
How did Repligen Corp RGEN's revenue perform in the last quarter?
Repligen Corp revenue for the last quarter is $0.48
What is the revenue estimate for Repligen Corp?
According to 20 of Wall street analyst, the revenue estimate of Repligen Corp range from $213.57M to $195.65M
What's the earning quality score for Repligen Corp?
Repligen Corp has a earning quality score of B/43.906578. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Repligen Corp report earnings?
Repligen Corp next earnings report is expected in 2026-08-03
What are Repligen Corp's expected earnings?
Repligen Corp expected earnings is $196.12M, according to wall-street analysts.
Did Repligen Corp beat earnings expectations?
Repligen Corp recent earnings of $194.25M does not beat expectations.